ICH Guideline E14/S7B: Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential — Q&A Step 5
On 24 March 2022 the EMA published the ICH Q&A guideline E14/S7B.
Read the pdf
Read
Emergency Use Authorization for Vaccines to Prevent COVID-19
On 31 March 2022 the FDA published final guidance for industry.
Read more online
Read
Clinical Trials in Human Medicines: Management of Clinical Trials Impacted by the War in Ukraine
On 31 March 2022 the FDA published the advice to sponsors on management of clinical trials impacted by the war in Ukraine.
Read more online
Read
Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry
On 1 March 2022 the FDA published the final guidance for industry.
Read more online
Read
Pre-Launch Activities Importation Requests (PLAIR)
On 1 March 2022 the FDA published the final guidance on the PLAIR for industry.
Read more online
Read
Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics
On 1 March 2022 the FDA published the final guidance for industry.
Read more online
Read
Inclusion of Older Adults in Cancer Clinical Trials
On 2 March 2022 the FDA published the final guidance for industry.
Read more online
Read
Unique Identification Number (CHRN – Swiss Single Registration Number)
On 3 March 2022 the Swissmedic updated the guidance on the unique Swiss Single Registration Number for medical devices.
Read more online
Read
Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs
On 9 March 2022 the FDA published draft guidance for industry. Comments may be submitted until 9 May 2022.
Read more online
Read
Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations: Enforcement Policy Regarding Certain Provisions
On 11 March 2022 the FDA published the final guidance for industry.
Read more online
Read
Compliance Monitor Process (Part 1) – An Introduction
On 11 March 2022 the MHRA Inspectorate Blog published part one of a two-part series on the Compliance Monitor Process.
Read more online
Read
Updated Guidelines on Good Pharmacovigilance Practices (GVP)
On 14 March 2022 the EMA issued an introductory cover note updating the release of Addendum III of Module XVI on pregnancy prevention programs for public consultation.
Read the pdf
Read
Human Gene Therapy Products Incorporating Human Genome Editing
On 15 March 2022 the FDA published draft guidance for industry.
Read more online
Read
Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products
On 15 March 2022 the FDA published draft guidance for industry.
Read more online
Read
EudraVigilance – EVWEB User Manual
On 15 March 2022 the EMA updated section 5.1 of the EVWEB reporting tool user manual.
Read the pdf
Read
Updated EMA Q&A: Good Clinical Practice (GCP)
On 15 March 2022 the EMA updated the GCP Q&A guidance.
Read more online
Read
Updated Clinical Pharmacology and Pharmacokinetics: Questions and Answers
On 16 February 2022 the EMA published updated Q&A guidance on expectations for bootstrapping to calculate the 90% confidence interval for the f2 similarity factor.
Read more online
Read
Eudralex Volume 4 – EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use
On 21 February 2022 the European Commission published Annex 21 of Eudralex Volume 4 EU guideline for GMP.
Read more online
Read
FDA Issues Proposal to Amend Medical Device Quality System Regulations
On 23 February 2022 the FDA issued an amendment proposal for medical device regulation. Comments on the proposed rule may be submitted until 24 May 2022. Comments (including recommendations) on the collection of information under the Paperwork Reduction Act of 1995 are accepted until 25 March 2022.
Read more online
Read
Updated EudraVigilance – EVWEB User Manual
On 23 February 2022 the EMA published version 1.6 of the EVWEB web reporting tool.
Read the pdf
Read
European Medicines Agency Guidance for Applicants Seeking Scientific Advice and Protocol Assistance
On 24 February 2022 the EMA published the updated guidance for scientific advice or protocol assistance procedures.
Read the pdf
Read
Patient-Focused Drug Development: Methods to Identify What Is Important to Patients
On 25 February 2022 the FDA published the final guidance for Industry, FDA staff and other stakeholders.
Read more online
Read
NMPA Guidance on Preparation of Pharmacovigilance
On 25 February 2022 the Center for Drug Reevaluation of Chinese NMPA published the notification on PSMF preparation guidance.
Read more online
Read
Procedural Advice – Extended Assessment Time for Initial Marketing Authorization Applications of 90 Days
On 25 February 2022 the EMA published the extended assessment time for initial marketing authorization applications.
Read the pdf
Read
Updated Questions and Answers Document – Clinical Trials Regulation (EU) 536/2014
On 1 February 2022 the European Commission published version 5 (January 2022) of the updated Q&A guidance on the Clinical Trials Regulation.
Read more online
Read
Clinical Trials Information System (CTIS): Updated Online Modular Training Program
On 3 February 2022 the EMA announced the availability of version 1.1 of online modular CTIS training program.
Read the pdf
Read
EudraVigilance: Obtaining EDQM terms from SPOR
On 3 February 2022 the EMA published the EudraVigilance guidance on obtaining EDQM terms from SPOR.
Read the pdf
Read
Mandatory Use of ISO ICSR/ICH E2B(R3) and EDQM Terminology for Dosage Forms (DF) and Routes of Administration (RoA)
On 3 February 2022 the EMA published guidance on the mandatory use of ISO ICSR/ICH E2B(R3) and EDQM Terminology for DF and RoA.
Read the pdf
Read
Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling–Content and Format
On 3 February 2022 the FDA published the draft guidance for industry. Comments accepted until 5 April 2022.
Read more online
Read
Assessment of Pressor Effects of Drugs
On 3 February 2022 the FDA published the draft guidance for industry.
Read more online
Read
Population Pharmacokinetics
On 3 February 2022 the FDA published the final guidance for industry.
Read more online
Read
Drug Product Tracing: The Effect of Section 585 of the FD&C Act
On 3 February 2022 the FDA published the final guidance on the Q&A.
Read more online
Read
Updated Reflection Paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials, with Particular Emphasis on the Handling of Expiry Dates
On 4 February 2022 the EMA announced the new version of the reflection paper on the use of IRTs in clinical trials.
Read the pdf
Read
Update – Guideline on the Requirements to Chemical and Pharmaceutical Quality Documentation Concerning Investigational Medicinal Products in Clinical Trials
On 4 February 2022 the European Commission announced the revision 2 on the requirements for quality documentation of chemical and pharmaceutical IMPs in clinical trials.
Read more online
Read
Update – Guideline on the Requirements for Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials
On 4 February 2022 the European Commission announced revision 2 on the requirements for quality documentation of biological IMPs in clinical trials.
Read more online
Read
Clinical Pharmacology Considerations for Antibody-Drug Conjugates
On 7 February 2022 the FDA published the draft guidance. Comments accepted through 6 May 2022.
Read more online
Read
Exporting Active Substances Manufactured in Great Britain for Use in EEA and Northern Ireland
On 7 February 2022 the MHRA updated guidance on how to implement the ‘Written Confirmation’ process for active substances manufactured in Great Britain.
Read more online
Read
Clinical Trials for Medicines: Manage your Authorization, Report Safety Issues
On 7 February 2022 the MHRA updated the guidance on managing the clinical trial authorization, reporting safety issues and completing the end-of-trial study report.
Read more online
Read
Joint Implementation and Preparedness Plan for Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices (IVDR)
On 7 February 2022 the European Commission announced an update of the joint implementation plan for IVDR.
Read more online
Read
Updated IRIS Guide for Applicants
On 7 February 2022 the EMA issued version 2.6 of the IRIS guide for applicants.
Read the pdf
Read
Initiation of DARWIN EU® Coordination Centre Advances Integration of Real-World Evidence into Assessment of Medicines in the EU
On 9 February 2022 the EMA announced the establishment of the Coordination Centre with Erasmus University Medical Center Rotterdam for the DARWIN EU.
Read more online
Read
Updated Guidance on the Management of Clinical Trials During the COVID-19 (Coronavirus) Pandemic
On 10 February 2022 the European Commission announced the updated guidance on the clinical trials management during the COVID-19 pandemic in Europa.
Read more online
Read
Update to Guidance Document: Risk Management Plan (RMP) ICH E2E Information for HMP Submission
On 15 February 2022 the Swissmedic announced the updated guidance on RMP ICH E2E submission information for human medicinal products.
Read more online
Read
Big Data Highlights – Issue 1
On 15 February 2022 the EMA published the first edition of the newsletter on Big Data.
Read the pdf
Read
EudraVigilance: Updated Electronic Reporting
On 15 February 2022 the EMA announced an update to electronic reporting in EudraVigilance.
Read more online
Read
Clinical Trials Information System (CTIS) Sponsor End User Training Program – March 2022
On 18 January 2022 the EMA announced the CTIS sponsor end user training program being held from 1 March to 4 March 2022, for the new way of submitting, managing and reporting a clinical trial via the CTIS.
Read more online
Read
Electronic Application Form (eAF) and Cover Letter Tool
On 20 January 2022 the MHRA updated the guidance on how to complete the eAF and cover letter.
Read more online
Read
Digital Health Technologies for Remote Data Acquisition in Clinical Investigations
On 21 January 2022 the FDA published the draft guidance for industry, investigators, and other stakeholders. Comments may be submitted until 22 March 2022.
Read more online
Read
Regulatory Harmonization of Clinical Trials in the EU: Clinical Trials Regulation to Enter into Application and new Clinical Trials Information System (CTIS) to be Launched
On 25 January 2022 the EMA released the news about the CTIS launching on 31 January 2022.
Read more online
Read
Revising ANDA Labeling Following Revision of the RLD Labeling
On 25 January 2022 the FDA published the draft guidance for industry. Comments may be submitted until 25 March 2022.
Read more online
Read
Patient Engagement in the Design and Conduct of Medical Device Clinical Studies
On 26 January 2022 the FDA issued the final guidance for industry, FDA staff, and other stakeholders.
Read more online
Read
Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation
On 26 January 2022 the FDA issued the final guidance for industry, FDA staff, and other stakeholders.
Read more online
Read
Principles of Premarket Pathways for Combination Products
On 26 January 2022 the FDA issued the final guidance for industry and FDA staff.
Read more online
Read
Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments
On 26 January 2022 the FDA issued the final guidance for industry.
Read more online
Read
Good ANDA Submission Practices
On 26 January 2022 the FDA issued the final guidance for industry.
Read more online
Read
Oversight and Monitoring of Investigational Medical Product (IMP) Trials
On 28 January 2022 the MHRA issued guidance to assist sponsors and those conducting trials on implementing adequate oversight and monitoring processes for trials of IMPs.
Read more online
Read
Risk-Adapted Approach to Clinical Trials and Risk Assessments
On 28 January 2022 the MHRA issued guidance on how to implement a dual strategy for a risk-adapted approach to clinical trials in the UK.
Read more online
Read
Guideline on Requirements for Chemical and Pharmaceutical Quality Documentation Concerning Investigational Medicinal Products (IMPs) in Clinical Trials
On 28 January 2022 the EMA published guidance to define harmonized requirements for documentation submitted throughout the EU.
Read the pdf
Read
Regulating Medical Devices in the UK
On 1 January 2022 the MHRA updated this guidance to reflect changes to the new medical device regulatory requirements.
Read more online
Read
eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Training
On 4 January 2022 the EMA updated the frequently asked questions about XEVMPD training.
Read the pdf
Read
Notify the MHRA about a Clinical Investigation for a Medical Device
On 4 January 2022 the MHRA updated the guidance on how to inform them of a clinical investigation of medical devices.
Read more online
Read
Investigational COVID-19 Convalescent Plasma
On 7 January 2022 the FDA published the final guidance for industry.
Read more online
Read
Clinical Trials for Medicines: How to Apply for Authorization in the UK
On 7 January 2022 the MHRA updated the guidance on the new combined review service.
Read more online
Read
European Commission Implementing Regulation (EU) 2022/20 of 7 January 2022 for Safety Assessment of Clinical Trials
On 10 January 2022 the EC released guidance on implementing the EU clinical trial regulation for Safety Assessment in Clinical Trials.
Read more online
Read
Accelerating Clinical Trials in the EU (ACT EU)
On 13 January 2022 the EMA launched an EU clinical trials transformation initiative.
Read the pdfRead more online
Read
EMA EudraVigilance Registration Manual
On 14 January 2022 the EMA updated the EudraVigilance registration manual.
Read the pdf
Read
Clinical Trials Information System (CTIS) Sponsor User Training Program - January 2022
On 14 January 2022 the EMA announced the CTIS sponsor user training program.
Read the pdf
Read
Referencing the Definition of “Device” in the Federal Food, Drug, and Cosmetic Act in Guidance, Regulatory Documents, Communications, and Other Public Documents
On 15 December 2021 the FDA published the draft guidance for industry and FDA staff. Comments may be submitted until 14 February 2022.
Read more online
Read
Updated Clinical Trials Information System: Training and Support
On 16 December 2021 the EMA updated the training support for CTIS.
Read more online
Read
ICH Guideline Q9 (R1) on Quality Risk Management
On 16 December 2021 the EMA issued the ICH guideline Q9(R1) on quality risk management (step 2b) for public comments. Comments may be submitted until 15 March 2022.
Read the pdf
Read
Inspection of Injectable Products for Visible Particulates
On 17 December 2021 the FDA published the draft guidance for industry. Comments may be submitted until 15 February 2022.
Read more online
Read
Guideline for the Notification of Serious Breaches of Regulation (EU) No 536/2014 or the Clinical Trial Protocol
On 17 December 2021 the EMA issued the final guideline for the notification of serious breaches of EU clinical trial regulation 536/2014 or the clinical trial protocol.
Read the pdf
Read
Progressive Roll-out of In Vitro Diagnostic Medical Devices Regulation
On 17 December 2021 the European Commission released the progressive roll-out of in-vitro diagnostic medical device regulations beginning 26 May 2022.
Read more online
Read
Clinical Drug Trial Investigator Charged with Insider Trading
On 20 December 2021 the U.S. Securities and Exchange Commission (SEC) disclosed insider trading charges against investigator.
Read more online
Read
Clinical Trials on Medicinal Products in Switzerland
On 20 December 2021 the Swissmedic announced the paperless submission as of 1 January 2022.
Read more online
Read
Digital Health Technologies for Remote Data Acquisition in Clinical Investigations
On 22 December 2021 the FDA published the draft guidance for industry, investigators, and other stakeholders. Comments may be submitted until 22 March 2022.
Read more online
Read
Technical Considerations for Medical Devices with Physiologic Closed-Loop Control Technology
On 22 December 2021 the FDA published the draft guidance for industry and FDA staff. Comments may be submitted until 22 February 2022.
Read more online
Read
Innovative Licensing and Access Pathway
On 30 December 2021, the UK MHRA updated the guidance on a new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
Read more online
Read
Widler & Schiemann AG Appoints Martin E. Zuzulo as New Managing Director - Americas
PRINCETON, NJ, January 4, 2022 – Widler & Schiemann AG is expanding its presence and portfolio of capabilities with the appointment of Martin E. Zuzulo as Managing Director-Americas.
Read
Clinical Trials Information System (CTIS) – Sponsor Handbook
On 2 December 2021 the EMA updated the CTIS sponsor handbook: a compilation of key guidance, technical information, recommendations and references for getting ready for use of CTIS.
Read the pdf
Read
Establishment and Operation of Clinical Trial Data Monitoring Committees
On 3 December 2021 the FDA published the final guidance for clinical trial sponsors.
Read more online
Read
ICMRA and WHO Map out Flexibilities Used by Regulators to Respond to the COVID-19 Pandemic
On 3 December 2021 the EMA announced the regulatory flexibilities to respond to the COVID-19 pandemic.
Read more online
Read
IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations
On 7 December 2021 the FDA published the draft guidance for industry. Comments may be submitted by 7 February 2022.
Read more online
Read
IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations
On 7 December 2021 the FDA published the draft guidance for industry. Comments may be submitted until 7 February 2022.
Read more online
Read
Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products
On 8 December 2021 the FDA published the draft guidance for industry. Comments may be submitted until 8 March 2022.
Read more online
Read
Development of Anti-Infective Drug Products for the Pediatric Population
On 9 December 2021 the FDA published the final guidance for industry.
Read more online
Read
CMC Postapproval Manufacturing Changes for Specified Biological Products to Be Documented in Annual Reports
On 9 December 2021 the FDA published the final guidance for industry.
Read more online
Read
Substantial Modification of Clinical Investigation under Medical Device Regulation
On 9 December 2021 the European Commission published the medical device coordination group (MDCG) document 2021-28.
Read the pdf
Read
Questions and Answers on Articles 13 & 14 of Regulation (EU) 2017/745 and Regulation (EU) 2017/746
On 9 December 2021 the European Commission published the medical device coordination group (MDCG) Q&A document 2021-27.
Read the pdf
Read
Cover Letter Attachments for Controlled Correspondences and ANDA Submissions Guidance for Industry
On 10 December 2021 the FDA published the draft guidance for industry. Comments may be submitted until 10 February 2022.
Read more online
Read
Q3C(R8) Impurities: Guidance for Residual Solvents
On 10 December 2021 the FDA published the final guidance for industry.
Read more online
Read
Highlights from the 16th EMA Industry Platform Meeting on the Operation of EU Pharmacovigilance Legislation
On 10 December 2021 the EMA published highlights from the 16th Pharmacovigilance Industry Platform meeting.
Read the pdf
Read
Global Reflections on International Inspection Transformation: ICMRA Remote Inspections
On 10 December 2021 the MHRA Inspectorate published an article by Paula Walker.
Read more online
Read
EU Country Health Profiles
On 13 December 2021 the European Commission released the 2021 edition of country health profiles.
Read more online
Read
Clinical Trials Information System (CTIS) Highlights
On 13 December 2021 the EMA published CTIS highlights.
Read the pdf
Read
Adjustments Required for Entering Drug Manufacturers into the EudraGMDP Database
On 14 December 2021 the Swissmedic announced the adaptation for the integration of the EudraGMDP with the organization management service (OMS).
Read more online
Read
MHRA Updated Guidance on Managing Clinical Trials during Coronavirus (COVID-19)
On 16 November 2021 the UK MHRA updated the Urgent Safety Measures section of its guidance on managing clinical trials during COVID-19.
Read more online
Read
IRIS Guide for Applicants
On 24 November 2021 the EMA updated the IRIS guide for applicants, version 2.4.
Read the pdf
Read
Press Release: ICH Assembly Virtual Meeting, November 2021
On 25 November 2021 the ICH released the ICH assembly virtual meeting on 17 and 18 November.
Read more online
Read
EU Commission Implementing Regulation (EU) 2021/2078 re the Application of Regulation (EU) 2017/745 and the European Database on Medical Devices (Eudamed)
On 26 November 2021 the EC laid down rules for the application of Regulation (EU) 2017/745 and the European database on medical devices.
Read more online
Read